David R. D’Adamo - Concepedia

Author

David R. D’Adamo

Also Known As

Cherubino P., D. D'Adamo, D. D’Adamo, D. R. D'Adamo, D. R. D’Adamo, D.R. D'Adamo, David D'Adamo, David D'adamo, David D’Adamo, David R D'Adamo

Publications

6.7K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute Eisai (United States)Texas Oncology Massachusetts General Hospital

About

David R. D’Adamo is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	23	3.6K
2	Health Sciences	11	12	1.3K
3	Cell Biology	3	3	979
4	Gastroenterology	2	2	138
5	Natural Sciences	1	1	58

David R. D’Adamo

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
Crizotinib in<i>ALK</i>-Rearranged Inflammatory Myofibroblastic Tumor James E. Butrynski, David R. D’Adamo, Jason L. Hornick, New England Journal of Medicine Lymphoid NeoplasiaTumoral PathologyMalignant DiseaseAlk-translocated ImtPathology	2010	851
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial Patrick Schöffski, Sant P. Chawla, Robert G. Maki, The Lancet OncologyMetronomic TherapyPharmacologyAdvanced LiposarcomaEribulin Versus Dacarbazine	2016	753
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas Robert G. Maki, David R. D’Adamo, Mary Louise Keohan, Journal of Clinical Oncology Surgical OncologySarcoma SubtypeMalignant DiseaseMedicineDaily Oral Sorafenib	2009	569
Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Manish A. Shah, Ramesh K. Ramanathan, David H. Ilson, Journal of Clinical Oncology	2006	409
Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas Suzanne George, Priscilla Merriam, Robert G. Maki, Journal of Clinical Oncology Malignant DiseaseGastrointestinal OncologyMedicinePharmacologyDisease Control	2009	315
Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas David R. D’Adamo, Sibyl Anderson, Karen Albritton, Journal of Clinical Oncology	2005	252
Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis Mrinal M. Gounder, Robert A. Lefkowitz, Mary Louise Keohan, Clinical Cancer Research	2011	251
An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known <i>BRCA</i> Mutation: Clinical Descriptors, Treatment Implications, and Future Directions Maeve A. Lowery, David P. Kelsen, Zsofia K. Stadler, The Oncologist	2011	241
Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor) Veridiana Pires de Camargo, Mary Louise Keohan, David R. D’Adamo, Cancer	2010	212
A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma Robert G. Maki, Achim A. Jungbluth, Sacha Gnjatic, Sarcoma Tumor Response RateImmunologyImmunoeditingPathologyRecist Response Rate	2013	179

Page 1